treatment decisions

  •  

    A New Champion for Cancer Caregivers

    With: Mike Looney, PhD

    Many people with advanced cancer can benefit from helpful caregivers, but family and friends who take on this role may have little background or training to do such a difficult job well. A new organization called Courage Groups aims to provide education and guidance in this collaborative journey. The founder is Mike Looney, PhD, a client and generous supporter of Cancer Commons, whose family… Read more »

  •  

    Caregivers, You’re Not Alone: Webinar Highlights

    Sarah Stanley

    Ten years ago, Shelley Frisbie’s husband received a diagnosis of metastatic cancer and was told he had six months to live. Shelley and her husband immediately faced immense urgency and uncertainty. But with guidance from Cancer Commons founder Marty Tenenbaum, PhD, Shelley soon had a list of top resources, doctors, and medical institutions to consult for help with her husband’s case. “I now had… Read more »

  •   Emma Shtivelman, PhD

    Excerpt from MedPage Today:

    “A high proportion of men who entered active surveillance for early prostate cancer had one or more high-risk disease characteristics when they subsequently had radical prostatectomy, a Swedish study showed.

    “Medical records showed that 52 of 132 men had at least one adverse pathology feature at radical prostatectomy. All the men initially opted for active surveillance, and the median time from enrollment to surgery was 1.9 years.”

    Go to full article published by MedPage Today on Sep 21, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from Healio:

    “An online prognostic tool accurately determined the risk for late distant recurrence among women with ER-positive breast cancer, according to a single-arm, prospective study.

    “The Clinical Treatment Score post-5 years (CTS5) tool could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment.”

    Go to full article published by Healio on Sep 19, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.